QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-maintains-sell-on-integra-lifesciences-lowers-price-target-to-20

BTIG analyst Ryan Zimmerman maintains Integra Lifesciences (NASDAQ:IART) with a Sell and lowers the price target from $22 to...

 citigroup-maintains-sell-on-integra-lifesciences-lowers-price-target-to-20

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and lowers the price target from $...

 jmp-securities-maintains-market-outperform-on-integra-lifesciences-lowers-price-target-to-35

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the pr...

 truist-securities-maintains-hold-on-integra-lifesciences-lowers-price-target-to-26

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price tar...

 citigroup-downgrades-integra-lifesciences-to-sell-lowers-price-target-to-23

Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and lowers the price tar...

 btig-downgrades-integra-lifesciences-to-sell-announces-22-price-target

BTIG analyst Ryan Zimmerman downgrades Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and announces $22 price target.

 integra-lifesciences-expects-fy24-revenue-of-1609b-1629b-prior-1672b-1687b-vs-1676b-est-adj-eps-of-241-257-prior-301-311-vs-304-est

2024 Outlook For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to $1.609 to $1.629 bil...

 integra-lifesciences-expects-q3-revenue-of-372m-382m-vs-43211m-est-adj-eps-of-036-044-vs-085-est

2024 Outlook For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to $1.609 to $1.629 bil...

 truist-securities-maintains-hold-on-integra-lifesciences-raises-price-target-to-32

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price tar...

 morgan-stanley-maintains-underweight-on-integra-lifesciences-raises-price-target-to-27

Morgan Stanley analyst Drew Ranieri maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and raises the price tar...

 integra-lifesciences-provides-updated-plans-to-restart-the-manufacture-of-primatrix-and-surgimend-at-its-new-manufacturing-facility-in-braintree-massachusetts

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is announcing its plans t...

 citigroup-maintains-neutral-on-integra-lifesciences-raises-price-target-to-30

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and raises the price target fro...

 citigroup-maintains-neutral-on-integra-lifesciences-raises-price-target-to-28

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and raises the price target fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION